Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition, comprising:

a substantially spherical polymer particle comprising a cross-linked polymer matrix and having a diameter of about 1200 microns or less,

wherein the particle contains an agent comprising a radioactive species,

the particle includes a first region including pores having a first predominant pore size and a second region surrounding the first region and including pores having a second predominant pore size, and

the first predominant pore size is larger than the second predominant pore size.

2. (Cancelled).

3. (Original) The composition of claim 1, wherein the agent comprises a therapeutic agent.

4. (Original) The composition of claim 1, wherein the radioactive species comprises a radioactive molecule.

5. (Original) The composition of claim 1, wherein the radioactive species comprises a radioisotope.

6. (Original) The composition of claim 5, wherein the radioisotope is selected from the group consisting of yttrium (^{90}Y), lutetium (^{177}Lu), actinium (^{225}Ac), praseodymium, astatine (^{211}At), rhenium (^{186}Re), bismuth (^{212}Bi or ^{213}Bi), holmium (^{166}Ho), samarium (^{153}Sm), iridium (^{192}Ir), rhodium (^{105}Rh), iodine (^{131}I or ^{125}I), indium (^{111}In), technetium (^{99}Tc), phosphorus (^{32}P), sulfur (^{35}S), carbon (^{14}C), tritium (^{3}H), chromium (^{51}Cr), chlorine (^{36}Cl), cobalt (^{57}Co or ^{58}Co), iron (^{59}Fe), selenium (^{75}Se), and gallium (^{67}Ga).

7. (Original) The composition of claim 5, wherein the radioisotope is bound to an antibody.

8. (Previously Presented) The composition of claim 7, wherein the antibody is selected from the group consisting of anti-PSMA, antibodies to CD20, antibodies to CD74 and antibodies to CD52 antigens.

9. (Original) The composition of claim 7, wherein the antibody is a monoclonal antibody.

10. (Previously Presented) The composition of claim 9, wherein the monoclonal antibody is selected from the group consisting of antibodies to CD20, antibodies to CD74, and antibodies to CD52 antigens.

11. (Original) The composition of claim 1, wherein the polymer is selected from the group consisting of polyvinyl alcohol, polycaprolactone, polylactic acid and poly(lactic-co-glycolic) acid.

12. (Original) The composition of claim 1, wherein the polymer comprises polyvinyl alcohol.

13. (Original) The composition of claim 1, wherein the agent is in an interior of the particle.

14. (Original) The composition of claim 1, wherein the agent is on a surface region of the particle.

15. (Currently Amended) A method comprising:

delivering to a subject a composition that comprises a substantially spherical polymer particle comprising a cross-linked polymer matrix and having a diameter of about 1200 microns or less,

wherein the particle contains an agent comprising a radioactive species,

the particle includes a first region including pores having a first predominant pore size and a second region surrounding the first region and including pores having a second predominant pore size, and

the first predominant pore size is larger than the second predominant pore size.

16. (Cancelled).

17. (Original) The method of claim 15, wherein the agent comprises a therapeutic agent.

18. (Original) The method of claim 15, wherein the radioactive species comprises a radioactive molecule.

19. (Original) The method of claim 15, wherein the radioactive species comprises a radioisotope.

20. (Original) The method of claim 15, wherein the composition is used to treat a cancer condition.

21. (Original) The method of claim 20, wherein the cancer condition is selected from the group consisting of ovarian cancer, colorectal cancer, thyroid cancer, gastrointestinal cancer, breast cancer, prostate cancer and lung cancer.

22. (Original) The method of claim 15, wherein the radioisotope is bound to an antibody.

23. (Original) The method of claim 22, wherein the antibody is capable of binding to one or more antigens at a treatment site of the subject.

24. (Original) The method of claim 23, wherein the radioactive species is released at the treatment site.

25. (Previously Presented) The method of claim 15, wherein the composition is delivered by puncturing the skin and injecting the composition.

26. (Original) The method of claim 15, wherein the composition is delivered by a catheter.

27. (Currently Amended) A method of making a composition, the method comprising:
disposing a radioactive species in a substantially spherical polymer particle comprising a cross-linked polymer matrix and having a diameter of about 1200 microns or less,

wherein the particle includes a first region including pores having a first predominant pore size and a second region surrounding the first region and including pores having a second predominant pore size, and

the first predominant pore size is larger than the second predominant pore size.

28. (Cancelled).

29. (Original) The method of claim 27, wherein the radioactive species comprises a therapeutic agent.

30. (Original) The method of claim 27, wherein the radioactive species comprises a radioactive molecule.

31. (Original) The method of claim 27, wherein the radioactive species comprises a radioisotope.

32. (Original) The method of claim 27, further comprising disposing the radioactive species on a surface region of the particle.

33. (Currently Amended) A method of making a composition, the method comprising:

disposing a radioactive species on a surface region of a substantially spherical polymer particle comprising a cross-linked polymer matrix and having a diameter of about 1200 microns or less,

wherein the particle includes a first region including pores having a first predominant pore size and a second region surrounding the first region and including pores having a second predominant pore size, and

the first predominant pore size is larger than the second predominant pore size.

34. (Cancelled).

35. (Original) The method of claim 33, wherein the radioactive species comprises a therapeutic agent.

36. (Original) The method of claim 33, wherein the radioactive species comprises a radioactive molecule.

37. (Original) The method of claim 33, wherein the radioactive species comprises a radioisotope.